文献速递哮喘

成人哮喘吸入性糖皮质激素治疗:需要新的治疗剂量术语

Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

本文指出GINA指南沿用「低」「中」「高」剂量术语定义成人哮喘吸入性糖皮质激素(ICS)日维持剂量(丙酸氟替卡松100-250 μg、>250-500 μg、>500 μg或等效剂量)缺乏证据基础,可能导致不适当过量用药。作者提出以「标准日剂量」(丙酸氟替卡松200-250 μg或等效剂量)重新分类,该剂量可获得约80-90%最大治疗获益,建议起始治疗及第2、3级维持治疗采用此剂量。

要点

  • 现行ICS「低」「中」「高」剂量术语缺乏证据基础,可能导致过量处方。
  • 「标准日剂量」丙酸氟替卡松200-250 μg或等效剂量可获得约80-90%最大治疗获益。
  • 建议起始ICS治疗及第2、3级维持治疗采用标准日剂量,第4级可考虑更高剂量。

核心结论

  • 现行ICS「低」「中」「高」剂量术语非证据基础,处方实践可能使用不适当过量剂量。
  • 提出以「标准日剂量」(丙酸氟替卡松200-250 μg或等效剂量)重新分类ICS剂量。

研究设计与样本

  • 简洁临床综述,未报告系统检索范围或样本量。

主要发现

  • 达到80-90%最大可获得获益的ICS剂量目前被归类为低剂量,而中、高剂量伴有显著全身不良反应风险。
  • 标准日剂量定义为丙酸氟替卡松200-250 μg或等效剂量,在成人哮喘全严重度范围内可获得约80-90%最大治疗获益。

关键数值与推荐

  • GINA指南传统术语:成人哮喘ICS日维持剂量低剂量为丙酸氟替卡松100-250 μg或等效剂量。
  • GINA指南传统术语:中剂量为>250-500 μg,高剂量为>500 μg(丙酸氟替卡松或等效剂量)。
  • 提议标准日剂量:丙酸氟替卡松200-250 μg或等效剂量。
  • 建议起始ICS治疗采用标准日剂量,第2级维持及第3级ICS/长效β2受体激动剂联合治疗采用此剂量。
  • 第4级可按阶梯方案在ICS/长效β2受体激动剂维持治疗中处方更高剂量。

临床怎么用

  • 哮喘指南和临床处方实践需根据现有ICS剂量-反应关系证据进行修改。
  • 起始ICS治疗及第2、3级维持治疗推荐采用标准日剂量(丙酸氟替卡松200-250 μg或等效剂量)。

局限性

  • 原文未报告综述的检索范围、纳入标准或证据质量评价方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Global Initiative for Asthma guidelines use the traditional terminology of "low," "medium," and "high" doses of inhaled corticosteroids (ICS) to define daily maintenance doses of 100 to 250 μg, >250 to 500 μg, and >500 μg, respectively, of fluticasone propionate or equivalent for adults with asthma. This concise clinical review proposes that this terminology is not evidence based and that prescribing practice based on this terminology may lead to the use of inappropriately excessive doses of ICS. Specifically, the ICS dose that achieves 80-90% of the maximum obtainable benefit is currently classified as a low dose, with the description of two higher dose levels of medium and high, which are associated with significant risk of systemic adverse effects. Asthma guidelines and clinician prescribing practice need to be modified in accordance with the currently available evidence of the dose-response relationship of ICS in adult asthma. We propose a reclassification of ICS doses based on a "standard daily dose," which is defined as 200-250 μg of fluticasone propionate or equivalent, representing the dose at which approximately 80-90% of the maximum achievable therapeutic benefit of ICS is obtained in adult asthma across the spectrum of severity. It is recommended that ICS treatment be started at these standard doses, which then represent the doses at which maintenance ICS are prescribed at step 2 and within ICS/long-acting β-agonist combination therapy at step 3. The opportunity is available to prescribe higher doses within ICS/long-acting β-agonist maintenance therapy in accordance with the stepwise approach to asthma treatment at step 4.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Beasley R, Harper J, Bird G, et al. Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology. Am J Respir Crit Care Med. 2019. PMID: 30645143. doi:10.1164/rccm.201810-1868CI

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。